<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903665</url>
  </required_header>
  <id_info>
    <org_study_id>FDZL-2021002</org_study_id>
    <nct_id>NCT04903665</nct_id>
  </id_info>
  <brief_title>PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I</brief_title>
  <official_title>Gynecologic Malignancies Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Burning Rock Bioengineering Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective study aimed to develop and validate the performance of combined&#xD;
      multi-omitcs assays for early detection of gynecologic cancers. Biomarkers of cfDNA&#xD;
      methylation, ctDNA mutation and blood miRNA markers will be evaluated. The study will enroll&#xD;
      approximately 495 female participants, including participants with gynecologic cancers or&#xD;
      benign diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity,specificity and tissue of origin accuracy of the multi-omics model as early detection for gynecologic cancers.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of the multi-omics model in early detection of gynecologic cancers in different stages.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of the multi-omics model in early detection of different gynecologic cancer diseases</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">495</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer Arm</arm_group_label>
    <description>Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign Arm</arm_group_label>
    <description>Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-cancer early detection test</intervention_name>
    <description>Blood collection and multi-cancer early detection testing</description>
    <arm_group_label>Benign Arm</arm_group_label>
    <arm_group_label>Cancer Arm</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, white blood cells and formalin fixed, paraffin embedded (FFPE) tumor tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants will be recruited from the participating medical center and assigned&#xD;
        into two arms, including participants with new diagnosis of gynecologic malignancies and&#xD;
        benign gynecologic diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Able to provide a written informed consent&#xD;
&#xD;
          -  Confirmed diagnosis or highly suspicious cases of gynecologic malignancies&#xD;
&#xD;
          -  No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood&#xD;
             draw&#xD;
&#xD;
        Exclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow&#xD;
             transplant or stem cell transplant&#xD;
&#xD;
          -  Recipients of blood transfusion within 7 days prior to study blood draw&#xD;
&#xD;
          -  Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to&#xD;
             diseases other than cancer&#xD;
&#xD;
        Inclusion Criteria for Benign Arm Participants:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Able to provide a written informed consent&#xD;
&#xD;
          -  Confirmed diagnosis of benign gynecologic diseases&#xD;
&#xD;
          -  No prior radical treatment of the benign diseases prior to study blood draw&#xD;
&#xD;
        Exclusion Criteria for Benign Arm Participants:&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow&#xD;
             transplant or stem cell transplant&#xD;
&#xD;
          -  Recipients of blood transfusion within 7 days prior to study blood draw&#xD;
&#xD;
          -  Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to&#xD;
             diseases other than cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohua Wu, M.D.&amp;Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecological Oncology, Fudan University Shanghai Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Wen, M.D.&amp;Ph.D.</last_name>
    <phone>+86-021-64175590(81007)</phone>
    <email>wenhao_fdc@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuzi Zhang, M.D.</last_name>
    <phone>+86-021-60293798</phone>
    <email>Z_Zhangyuzi@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Wen, M.D.</last_name>
      <phone>+86-021-64175590(81007)</phone>
    </contact>
    <contact_backup>
      <last_name>Yuzi Zhang, M.D.</last_name>
      <phone>+86-021-60293798</phone>
      <email>Z_Zhangyuzi@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gynecologic cancer</keyword>
  <keyword>early detection</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>cell-free DNA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

